TKI治疗晚期非小细胞肺癌患者免疫功能的变化及意义  

TKI Treatment Changes and Significance in Immune Function in Patients with Non-small Cell Lung Cancer

作　　者：万鹏[1] 李晶[1] 姜北[1] 巩平[2] 黄伟[2] 

机构地区：[1]石河子大学医学院,新疆石河子832000 [2]石河子大学医学院第一附属医院,新疆石河子832000

出　　处：《现代生物医学进展》2014年第4期768-771,共4页Progress in Modern Biomedicine

摘　　要：目的:通过观察晚期非小细胞肺癌患者TKI治疗前后外周血IgG、IgM、IgA、C3、C4、C-反应蛋白及CD3+、CD4+、CD8+、CD4+/CD8+细胞的表达变化,探讨TKI治疗对晚期非小细胞肺癌患者免疫功能的影响及意义。方法:检测TKI组30例非小细胞肺癌患者TKI治疗前、治疗一个月后外周血IgG、IgM、IgA、C3、C4、C-反应蛋白及CD3+、CD4+、CD8+、CD4+/CD8+细胞表达水平,分析表达变化及与疗效的关系。30例非小细胞肺癌患者作为对照组。结果:治疗前,TKI组与对照组IgG、IgM、IgA、C3、C4、C-反应蛋白水平基本正常,但CD4+细胞数量减低、CD4+/CD8+比值较低、CD8+细胞数量增高,两组相比IgG、IgM、IgA、C3、C4、C-反应蛋白、CD3+、CD4+、CD8+、CD4+/CD8+差异均无统计学意义(P>0.05);TKI治疗一个月后,TKI组与对照组IgG、IgM、IgA、C3、C4、C-反应蛋白水平无明显变化,而CD4+细胞数量增多、CD4+/CD8+较前增高,CD8+细胞数量较前减低,两组相比CD3+、IgG、IgM、IgA、C3、C4、C-反应蛋白差异无统计学意义(P>0.05),而CD4+、CD4+/CD8+、CD8+差异有统计学意义(P<0.01)。结论:TKI治疗后,晚期非小细胞肺癌患者细胞免疫功能得到改善,体现在CD4+、CD8+细胞数量的变化上,且TKI治疗的疗效可通过比较外周血CD4+、CD4+/CD8+、CD8+细胞表达变化体现。Objective： Through the observation of advanced non-small cell lung cancer patients TKI before and after treatment in peripheral blood lgG, IgM, IgA, C3, C4, C-reaction protein and CD3＋, CD4＋, CD8＋, CD4＋/CDS＋cell expression changes, we discuss TKI treatment for advanced non-small cell lung cancer on the immune function of influence and significance. Method： 30 cases of no n-small cell lung cancer patients were selected and their following factors were detected before treatment and after one month of therapy by hydrochloric acid erlotinib （TKI）, peripheral IgG, IgM, IgA, C3, C4, C-reaction protein and CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ cells express level, analyzes its expression changes and the relationship between changes and the therapy efficacy. 30 patients in non-small cell lung cancer patients were as control group. Results： Before treatment, TKI group and control group IgG, IgM, lgA, C3, C4, C - reaction protein level essentially normal, but the number of CD4＋ cells reduced, CD4＋/CD8＋ ratio was low, CD8＋ cells quantity increased, compared two groups, IgG, IgM, IgA, C3, C4, C-reaction protein, CD3＋, CD4＋, CD8~, CD4＋/CD8＋ differences were no statistical significance （P〉0.05）; TKI treatment after a month, TKI group and control group IgG, IgM, IgA, C3, C4, C - reaction protein level had no obvious change, but the number CD4＋ cells increased, CD4＋/CD8＋ ratio is previously high, the CD8＋ cells quantity is reduced, compared two groups, CD3＋, IgG, IgM, IgA, C3, C4, C - reaction protein difference were not statistically significant （P〉0.05）, but CD4＋, CD4＋/CD8＋, CD8＋ difference have statistical significance （P〈0.01）. Conclusion： After TKI treatment, advanced non-small cell lung cancer patients with cell immune function has been improved with the changes of the CD4＋ and CD8＋ cells, and TKI treatment efficacy can be relatively peripheral blood CD4＋, CD4＋/CD8＋, CD8＋ cells expression changes reflected.

关 键 词：TKI治疗 晚期非小细胞肺癌 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]